Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Benjamin Saxey

Clinical Nurse Specialist, Psychiatric/Mental Health Layton, UT Physician Assistant

NPI 1225482201 CMS profile 11112023

2950 N Church St Ste 101, Layton, UT 84040

Open in the dashboard

General payments

$6,509

354 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Saxey of Layton, UT is reported in the CMS Open Payments database as having received $6,509 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,644 90
2024 General $1,440 69
2023 General $1,282 70
2022 General $1,163 67
2021 General $980 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Saxey
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Benjamin Saxey were reported at $1,644. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Benjamin Saxey Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $980 $153 $44–$540 $132
2022 $1,163 $207 $60–$748 $149
2023 $1,282 $197 $55–$898 $160
2024 $1,440 $189 $49–$804 $164
2025 $1,644 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $919 57 payments
  2. Janssen Pharmaceuticals, Inc $748 39 payments
  3. Otsuka America Pharmaceutical, Inc. $747 37 payments
  4. Vanda Pharmaceuticals Inc. $607 28 payments
  5. Teva Pharmaceuticals USA, Inc. $560 36 payments
  6. Neurocrine Biosciences, Inc. $493 24 payments
  7. ITI, Inc. $366 21 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $331 16 payments
  9. Lundbeck LLC $309 20 payments
  10. Alkermes, Inc. $253 14 payments
  11. Other $1,177 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,509 354 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $756 44 payments
  2. REXULTI Psychiatry $728 36 payments
  3. SPRAVATO $607 29 payments
  4. FANAPT $607 28 payments
  5. INGREZZA $399 19 payments
  6. TRINTELLIX $331 16 payments
  7. Austedo XR $317 21 payments
  8. REXULTI Psychiatry $263 17 payments
  9. HETLIOZ $259 13 payments
  10. LYBALVI $218 12 payments
  11. Other $3,139 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

524

Median for Physician Assistant: 241

Drug cost

$45,279

Median for Physician Assistant: $4,110

Branded share of claims

19.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 15 $23,764
Lurasidone Hcl Generic 30 $9,410
Aripiprazole Generic 19 $6,153
Bupropion Xl Bupropion Hcl Brand 35 $852
Clonazepam Generic 79 $641
Ziprasidone Hcl Generic 11 $596
Divalproex Sodium Generic 17 $468
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 16 $454
Trazodone Hcl Generic 90 $411
Venlafaxine Hcl Er Venlafaxine Hcl Brand 24 $370

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$7,976

Medicare's payments for the services billed

Medicare patients

12

Average age 61

Services billed

219

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $297
$297 15 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $95
  • Lundbeck LLC $54
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $9
$158 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $156
$156 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $137
$137 — —
SUBLOCADE
  • Indivior Inc. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record